Cough syrup issue: Health ministry directs rational use of medication

Union health secretary convened a meeting with states to address drug quality after multiple child deaths linked to contaminated cough syrups like Coldrif, found with DEG/EG. States were directed on rational use, while DGHS advised against prescribing such medicines for children under two, emphasizing careful evaluation for older kids. Probes are underway, and some states have banned the syrups.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/fpu3oe4
via IFTTT

Read More

NSE to build Rs 380-crore facility for cancer treatment at Tata Memorial Centre

NSE will build a 380 crore rupee cancer treatment facility at Tata Memorial Hospital. This 11-storey block and bone marrow transplant centre will be in Navi Mumbai. It will serve 1.3 lakh outpatients and conduct over 600 BMTs annually. The facility will have 60 beds. Operations are expected to begin by July 2027.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/E3MQqC6
via IFTTT

Read More

India's TB fight gets a boost: New Made-in-India diagnostic tests cut cost & time

India's ICMR has validated two new indigenous TB diagnostic tools from Huwel Lifesciences. The Quantiplus MTB FAST kit offers cheaper, open-system RT-PCR testing on existing machines, while UniAMP MTB uses non-invasive tongue swabs for patient-friendly diagnosis. These innovations promise faster, more accessible, and affordable TB detection, boosting India's elimination efforts.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/HYprjS0
via IFTTT

Read More

Torrent Pharma gets demand notices totalling Rs 6.63 cr from NPPA

Torrent Pharmaceuticals reported receiving demand notices from the NPPA. The notices total over Rs 6.63 crore. They allege overcharging for five drugs between January 2016 and November 2018. The company stated these notices were received on October 3, 2025. Torrent Pharmaceuticals expects no material financial impact from this development.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/yrTJDqE
via IFTTT

Read More

Health Ministry confirms Diethylene Glycol beyond permissible limits in Coldrif cough syrup amid child deaths in Raj, MP

The Ministry of Health confirmed Coldrif Cough Syrup from Sresan Pharma's Kanchipuram unit contained diethylene glycol (DEG) above permissible limits, following investigations into child deaths in Madhya Pradesh and Rajasthan. Tamil Nadu banned its sale, halting production. Authorities initiated risk-based inspections and advised against prescribing cough syrup to children under two.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Q1aO7u2
via IFTTT

Read More

Tamil Nadu bans ''Coldrif'' cough syrup after child deaths in MP, Rajasthan

Tamil Nadu has banned the sale of 'Coldrif' cough syrup, manufactured by a city-based firm, following suspicions linking it to 11 child deaths in Madhya Pradesh and Rajasthan. Inspections were conducted, and samples are being tested for Diethylene Glycol. The Union Health Ministry also advised against prescribing cough and cold medications for children under two years.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/y2LmXx6
via IFTTT

Read More

Isabgol processors threaten to halt purchases from October 6 over GST

Isabgol processors threaten to halt purchases from farmers due to GST ambiguities, locking up capital for over a year. The industry, exporting ₹3,500 crore annually, faces financial stress and slowed exports as unclear classifications force them to pay GST on seeds, despite refunds. They demand government clarification.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/szVjFdB
via IFTTT

Read More

Indian Pharmaceutical Alliance appoints Zydus Lifesciences MD Sharvil Patel as new president

The Indian Pharmaceutical Alliance (IPA) has appointed Sharvil Patel of Zydus Lifesciences as its new President, with Glenn Saldanha of Glenmark as Vice President. This leadership transition occurs as the industry navigates GST reforms and strengthens its global position in specialty medicines. The new team aims to drive innovation, patient access, and quality healthcare solutions.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/h4iGfDN
via IFTTT

Read More

IPA names Zydus Lifesciences MD Sharvil Patel as President

Sharvil Patel is the new president of the Indian Pharmaceutical Alliance. He takes over from Samir Mehta. Glenn Saldanha becomes the vice president. The IPA represents 23 national pharmaceutical companies. The new team will build on reforms and breakthroughs. They will focus on innovation, patient access, and quality in healthcare.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/GYj4I3U
via IFTTT

Read More

Panacea Biotec gets supply order from UNICEF for oral polio vaccines worth Rs 315 cr

Panacea Biotec has received a long-term supply order from UNICEF. The order is for bivalent oral polio vaccines. It is valued at USD 35.65 million. Supplies will commence from April 2026 and continue until March 2030. This agreement covers vaccine requirements for UNICEF. The company will provide vaccines in 10 and 20 vial presentations.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Ra1qZi5
via IFTTT

Read More

Government invites proposals under PRIP scheme for industry, startup projects

The government has invited applications for its Rs 5,000 crore Pharma-MedTech innovation scheme, aiming to support around 300 projects in new medicines, biosimilars, and medical devices. Revised guidelines offer enhanced financial assistance for MSMEs and startups, including higher support for strategic priority areas. Applications opened on October 1 via a digital portal.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/zx32rmn
via IFTTT

Read More

Novo, Lilly weight-loss drugs should be first option obesity treatments, European doctors say

Semaglutide, the active ingredient in Novo's Wegovy and Ozempic, and tirzepatide, sold as Zepbound and Mounjaro by Lilly, are so effective that they should be the first choice in almost all cases when substantial weight loss is necessary, according to a new guideline from the European Association for the Study of Obesity published in Nature Medicine.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/MtGbVzl
via IFTTT

Read More

Pricing depends on the country, Bayer looks at affordability: Executive

India has evolved significantly in the clinical trial setting...we have a significant number of patients and trials running in IndiaAshraf Al-Ouf Head, Pharmaceutical Commercial Ops, APAC, Bayer

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/HNKCDW5
via IFTTT

Read More

'Contaminated' cough syrup linked deaths: NCDS collects water, entomological drug samples

NCDC collected water and entomological drug samples from Madhya Pradesh and Rajasthan after multiple children died of kidney failure, allegedly linked to contaminated cough syrup. These samples will be tested for infectious diseases, while state drug authorities await results from drug sample tests. Six children died in MP and one in Rajasthan, prompting a ban on 19 syrup batches.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Pf9E8HG
via IFTTT

Read More

Indian pharma Wockhardt seeks US approval for new drug to treat UTIs

Wockhardt has submitted a New Drug Application to the USFDA for its novel antibacterial agent, Zidebactam-Cefepime injection. This drug targets complicated urinary tract infections, including those caused by multidrug-resistant Gram-negative bacteria. This marks a significant milestone as the first USFDA NDA for a drug fully discovered and developed by an Indian pharmaceutical company, following successful global Phase III trials.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/RVx0eK2
via IFTTT

Read More

Bayer seeks approval for key heart drug in India

Pharmaceutical major Bayer has filed for Indian approval of its patented drug finerenone (Kerendia) to treat heart failure patients with LVEF of 40 and above. This move aims to address India's growing early-onset heart disease burden. Already approved for chronic kidney disease, Bayer anticipates approval for this new indication by year-end, following successful trials.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/dVobQRg
via IFTTT

Read More

Global report says 40% of clinicians in India could be using AI in work

Over 40 per cent of Indian clinicians are now using AI for work, a threefold increase from last year, surpassing global adoption rates. Despite this rapid embrace and optimism, challenges like clinician burnout and institutional gaps in AI training and governance remain. Experts urge focused action to translate digital health policies into effective practice.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/lMGQCHV
via IFTTT

Read More

To what extent will Trump's tariffs impact Indian pharma? Govt assesses likely cost

Union Commerce ministry says US tariffs on pharma imports will not significantly impact India. India exports generic drugs, less affected by new rules. The nation is diversifying trade to counter US policy shifts. New free trade agreements with EFTA and the UK will boost marine exports. This strategy aims to broaden India's global market reach.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/eTi4Nu3
via IFTTT

Read More

Managing diabetes early: A smart choice to consider

Early management of type 2 diabetes is crucial in India, where the disease poses a significant health and financial burden. Starting treatment promptly and adopting lifestyle changes can reduce long-term complications like heart disease and kidney failure. Proactive conversations with healthcare providers and adherence to treatment plans are essential for better health outcomes and reduced healthcare costs.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/FVeCJXm
via IFTTT

Read More

Lupin subsidiary inks pact to acquire Netherlands-based VISUfarma

Lupin's subsidiary will acquire VISUfarma BV for 190 million euros. This expands Lupin's European business and eye health product range. The acquisition strengthens Lupin's specialty franchise. It will enter the ophthalmology market. The deal is expected to close by late 2025. This transaction will enhance Lupin's growth and margin profile.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/CniF2oE
via IFTTT

Read More

'Indian generics safe, tariffs unwise': Indian pharma association hits back after US tariff concerns

India's pharmaceutical industry, through the IPA, strongly countered US concerns regarding the quality of generic medicines, warning that tariffs would jeopardize America's drug security and increase reliance on China. The IPA cited FDA reports and independent testing affirming Indian facilities' high standards, highlighting billions saved for the US healthcare system.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/WNlVZxP
via IFTTT

Read More

Veterinary vaccine firms form association for collaboration with policymakers

India's leading veterinary vaccine manufacturers, including Hester Biosciences and Indian Immunologicals, have formed the Veterinary Vaccine India Manufacturers Association (VVIMA). This new association will serve as the industry's collective voice, aiming to collaborate with policymakers to foster innovation and position India as a global hub for animal vaccine research and production. Rajiv Gandhi leads as President.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/q6S4p0g
via IFTTT

Read More

Glenmark, Granules, Zydus recall products in US over manufacturing issues: USFDA

Indian drugmakers Glenmark, Granules India, Sun Pharma, Zydus, and Unichem are recalling various products in the US market due to manufacturing issues. These include CGMP deviations, failed impurity specifications, and label mix-ups, leading to Class I, II, and III recalls initiated from late August to mid-September. The USFDA reported these voluntary actions.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Qt7GKTg
via IFTTT

Read More

Highs & Lows: Could the microdosing of psychedelics be a key missing piece in the mental health jigsaw?

A Netflix documentary highlights the re-evaluation of mind-expanding substances like LSD, once banned but now experiencing a scientific renaissance. New research, including a study on pharmaceutical LSD for anxiety, suggests these psychedelics could redefine mental health treatment. However, overcoming public demonization and ensuring rigorous scientific trials are crucial for their widespread acceptance.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/lMRoBPA
via IFTTT

Read More

Just like bad medicine...Trump tariff pricks again; India not seen badly hit by US’ latest salvo

US President Trump’s 100% tariff on pharmaceutical products targets only branded and patented drugs, leaving India’s generic exports largely unaffected, experts say. The tariff, effective October 1, spooked pharma stocks but poses minimal immediate risk. India exported $9.8 billion in pharma to the US in FY25. Tariffs on furniture and trucks may benefit India, while bilateral trade talks continue.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/BroP82Q
via IFTTT

Read More

Weight-loss drug Ozempic to debut in India soon

Novo Nordisk will launch Ozempic in India. This injectable drug manages type 2 diabetes and aids weight loss. It enters a competitive market against Eli Lilly's Mounjaro. Novo Nordisk's Wegovy also competes. The company's semaglutide patent expires next year, allowing generic versions. India has a large population with diabetes and obesity. Ozempic offers significant health benefits.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ZgRvDCk
via IFTTT

Read More

Diabesity: It’s more than you think

The intertwined rise of obesity and type 2 diabetes, termed 'diabesity,' presents a significant health challenge in India. This condition, driven by complex factors beyond lifestyle, faces stigma hindering effective treatment. Indians, despite appearing thin, often have higher body fat, increasing their risk.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ezLwAQI
via IFTTT

Read More

Trump delivers another bitter tariff pill. Who’s set to bite the dust?

A new tariff announced by President Trump will impose a 100% levy on patented pharmaceuticals entering the U.S. from October 1, 2025, unless companies have manufacturing facilities in the country. This policy raises uncertainties about which drugs will be affected and challenges the Indian pharmaceutical sector, which significantly contributes to the U.S. market—supplying 47% of generics and saving the U.S. healthcare system $219 billion in 2022.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/vjyk36t
via IFTTT

Read More

Trump's 100% tariff on pharma will not impact generic makers, says Indian Pharma Alliance

The Indian Pharmaceutical Alliance clarifies that Trump's proposed 100% tariff targets patented and branded drugs, not generics, potentially impacting a segment of Indian exports. While the immediate effect on Indian exports may be limited due to their focus on generics and existing US manufacturing presence, the industry is advised to prepare for future policy changes and explore advanced pharmaceutical opportunities.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Ctv2JXp
via IFTTT

Read More

Meril’s Mizzo Endo 4000 sets a new benchmark in robotic surgery

Meril, an Indian medical device company, has launched the Mizzo Endo 4000, a next-generation surgical robotic system. This advancement aims to enhance surgical precision and accessibility across various specialties. The system features AI-powered 3D mapping, an open console, and 5G-enabled telesurgery.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/bj4wYEX
via IFTTT

Read More

Alembic Pharma gets USFDA nod for generic drug to treat depression, anxiety

Alembic Pharmaceuticals Ltd. announced it has secured final approval from the USFDA for its generic Paroxetine extended-release tablets, available in 25 mg and 37.5 mg strengths. These tablets are therapeutically equivalent to Apotex Inc's Paxil CR and indicated for treating major depressive disorder, panic disorder, social anxiety disorder, and premenstrual dysphoric disorder.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/hfOoZ9A
via IFTTT

Read More

HIV-prevention drug to cost $40 a year from 2027

The two organizations have signed separate agreements with Indian pharmaceutical companies to produce cheaper generics of lenacapavir - a twice-yearly injection shown to reduce the risk of HIV transmission by more than 99.9% - for low- and middle-income countries.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/RF2o8l5
via IFTTT

Read More

HCA Healthcare to invest $75 mln to set up Global Capability Center (GCC) in Hyderabad

HCA Healthcare inaugurated its Global Capability Center in Hyderabad, investing USD 75 million by 2025. The center, spanning 400,000 square feet, will employ 3,000 professionals by 2026, focusing on IT, supply chain, and finance. This strategic hub aims to drive innovation and operational excellence, supporting HCA Healthcare's patient care in the US and UK.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/qXJHxSn
via IFTTT

Read More

Tata 1mg likely to get $200 mn booster shot; Novo, CPPIB, Permira and ChrysCap line up

Novo Holdings, CPPIB, Permira, and ChrysCapital have shown interest in investing in Tata Group’s online pharmacy 1mg, which seeks up to $200 million for its next growth phase. The investors, however, consider the $1.25 billion 2022 valuation too high, proposing $750–800 million instead. Some also want board seats, which Tata is unwilling to offer.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/XtG0F8J
via IFTTT

Read More

India’s liver-heart-diabetes triangle: Why acting early could save your life

In India's bustling cities like Mumbai, a concerning trend emerges as fatty liver disease, now termed MASLD, quietly rises alongside diabetes and heart disease. Sedentary lifestyles, poor diets, and lack of awareness contribute to its prevalence, even among those with normal weight.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/vZsWTFx
via IFTTT

Read More

Vidal Health and Serum Institute collaborate on HPV vaccine access

Vidal Health, in partnership with Serum Institute of India, will launch a digital platform on October 1, 2025, to streamline HPV vaccine access and promote cervical cancer prevention. The platform offers convenient appointment booking, digital consent, and certification, ensuring a cashless and paperless experience. This collaboration aims to improve vaccine delivery efficiency and awareness, supporting national healthcare efforts.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/X5jEeYA
via IFTTT

Read More

India’s cheap birth control pills in US could vanish under Trump’s 250% tariff threat

Donald Trump's tariff threat jeopardizes affordable Indian medicines in the US. Birth control pills, hypertension, and depression treatments are most vulnerable. India, the world's pharmacy, faces potential export losses. Analysts foresee price hikes and supply chain disruptions. Indian firms may struggle to absorb tariffs. The US aims to boost domestic drug production. This move risks higher drug prices for Americans.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/GdbjFB0
via IFTTT

Read More

India’s unique diabetes profile: The Indian diabetes phenotype—why our bodies react differently

Diabetes is rapidly increasing in India, affecting over 101 million people, often manifesting differently than in the West. Indians tend to develop diabetes earlier, even at lower weights, due to a "thin-fat" body type and less muscle mass. Genetic predispositions, poor early-life nutrition, and sedentary lifestyles contribute to this alarming trend, with many unaware of their condition.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/cF9BOZp
via IFTTT

Read More

Drug companies flag concerns over timeline for carrying out regulator's manufacturing rule

Small and medium pharmaceutical companies are appealing to the health minister, raising concerns about stringent manufacturing standards imposed by the central drug regulatory body. These associations fear that the abrupt implementation timeline will force many MSMEs to shut down due to financial constraints and inability to meet the new requirements, potentially leading to medicine shortages.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Er6lSsU
via IFTTT

Read More

PE fund KKR closes third buy in Kerala, at Meitra Hospital

KKR, buoyed by its successful Max Healthcare exit, is expanding its hospital investments in South India. Its Kerala-based Baby Memorial Hospital (BMH) has acquired a majority stake in Meitra Hospital for ₹1,000-1,200 crore and is considering acquiring Star Care Hospital.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/wRNYXId
via IFTTT

Read More

Rehabilitation: India's 'missing link' in healthcare

Experts at the IAPMR Mid-Term CME 2025 highlighted India's rehabilitation shortage, emphasizing that discharge is not the end of treatment. The lack of structured rehabilitation, inadequate insurance coverage, and the removal of PMR from the medical curriculum are contributing to delayed recovery and frequent readmissions. They advocate for mandatory rehabilitation protocols and increased awareness to improve patient outcomes.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/N0Gu4Fn
via IFTTT

Read More

India push into global natural healthcare market, government research institutions develop new drugs

India's herbal healthcare sector is preparing for a new growth phase, as traditional medicine blends with modern science to produce validated, affordable, and globally competitive solutions. This momentum was on full display at the recently concluded two-day CSIR Startup Conclave, where research institutions, startups, and policymakers joined forces to demonstrate how herbal formulations are moving from laboratories to the marketplace.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3sZLo72
via IFTTT

Read More

"Transformative shift in India's healthcare": Pharma alliance lauds GST reforms ahead of implementation

The Indian Pharmaceutical Alliance lauds the upcoming GST reforms, effective Monday, as a transformative step towards affordable healthcare. Prime Minister Modi's initiative reduces GST on most medicines from 12% to 5%, with complete exemption for 36 critical life-saving drugs.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/JgbqhIT
via IFTTT

Read More

Healthcare set to be more affordable as new GST rate kicks in from Sep 22: Pharma industry

From September 22, medicines and medical devices in India will become cheaper under new GST rates, making healthcare more affordable, say industry experts. Most drugs’ GST drops from 12% to 5%, while 36 critical life-saving medicines are fully exempt. Tax slabs on insurance, glucometers, and spectacles are also rationalised, easing costs for patients and improving access to essential care.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/dsCrcVk
via IFTTT

Read More

Fermenta board approves sale of environmental solutions biz to subsidiary

Fermenta Biotech on Friday said its board has approved transferring its environmental solutions business to a wholly owned subsidiary on a slump sale basis, effective October 1, 2025.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/gJwf19o
via IFTTT

Read More

Fire at subsidiary unit temporarily hits production: Aurobindo Pharma

Aurobindo Pharma reported a fire incident on September 18, 2025, at its APL Healthcare Unit-IV in Andhra Pradesh due to a short circuit, causing temporary production disruption. The fire, contained with no casualties, impacted two out of nineteen lines, resulting in an estimated 3% reduction in monthly capacity. Refurbishment is underway, with operations expected to resume in a few weeks.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/aZvj2Ar
via IFTTT

Read More

PMO acts on pharma MSMEs 'crisis call'

The PMO has been alerted to potential medicine shortages and price increases due to stringent regulatory actions on pharmaceutical quality. The Federation of Pharma Entrepreneurs warns that many MSMEs face closure due to costly GMP upgrades, potentially impacting the supply of essential medicines and causing significant job losses. They are urging the government to extend the compliance deadline.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/gWrq3Yc
via IFTTT

Read More

Indian pharma sector to log 7-9% growth in FY26 despite US headwinds: ICRA

India's pharmaceutical industry is set to record healthy revenue growth of 7-9 per cent in FY26, even as challenges in the United States market continue to weigh on performance, noted rating agency ICRA in its latest sector outlook.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/7iWKYxw
via IFTTT

Read More

Natco Pharma's Kothur unit classified as 'voluntary action indicated' by US regulator

Natco Pharma Ltd announced that its Kothur unit in Hyderabad received an Establishment Inspection Report (EIR) from the US FDA, classifying the facility as 'Voluntary Action Indicated' (VAI). The US FDA had previously conducted an inspection of the company's pharma division at the Kothur location. While objectionable conditions were noted, the agency does not plan immediate regulatory action.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/8N9RW41
via IFTTT

Read More

India ranks among top contributors in reporting adverse events: Drugs Controller General of India

DCGI Dr. Rajeev Raghuvanshi highlighted India's leading role in global adverse event reporting during the 5th National Pharmacovigilance Week. The week-long campaign, themed 'Your Safety, Just a Click Away: Report to PvPI', aims to encourage ADR reporting through simplified digital platforms.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3KpDS7x
via IFTTT

Read More

AstraZeneca's asthma drug fails 'smoker's lung' study

AstraZeneca's Fasenra failed to reduce flare-ups in COPD patients in a late-stage trial, a setback for the company's efforts to address the severe lung disease. Despite this, AstraZeneca will analyze the data to understand the results better, while its rare disease drug Saphnelo succeeded in a lupus trial.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/5ZxtNuS
via IFTTT

Read More

'Nimesulide' may come with warning label

Indian drug regulators have mandated cautionary labels for nimesulide, restricting its use as a second-line treatment for patients 12 years and older after exhausting first-line options. The labels must warn against use during pregnancy, lactation, or by women planning pregnancy, as well as in patients with renal or hepatic impairment.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Jh9fwUT
via IFTTT

Read More

Novo Nordisk to test weight-loss drugs in broader range of obesity-linked conditions

Novo Nordisk is broadening its focus beyond obesity and diabetes by exploring the potential of its weight-loss drugs, including Wegovy, to treat conditions like knee osteoarthritis and sleep apnea. Clinical trials are planned to investigate the impact of CagriSema and amycretin on various obesity-related comorbidities.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/js6zR2W
via IFTTT

Read More

Scheme to promote innovation in pharma, medtech sectors to be launched this month: Pharma Secretary

The government will soon launch a scheme to boost innovation in the pharmaceutical and medical technology sectors. The PRIP scheme has a financial outlay of Rs 5,000 crore. It will support research and development. The scheme aims to reduce reliance on imports. Three medical device parks are expected to be functional by early 2027.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/hQu1WPy
via IFTTT

Read More

In major move, patent of Novartis' blockbuster cardiac drug revoked by India

The Indian Patent Office revoked Novartis' patent for Vymada, a heart failure drug, citing a lack of novelty and inventive step. This decision paves the way for generic versions, potentially lowering treatment costs for Indian patients. Domestic pharmaceutical companies had challenged the patent, arguing it violated Section 3(d) of the Patents Act, which prevents 'evergreening'.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/wnIFz8S
via IFTTT

Read More

Novo Holdings in talks to buy into Surya Hospitals

Novo Holdings is in exclusive discussions to acquire a 49% stake in Surya Hospitals, valuing the Mumbai-based chain at ₹1,000 crore. This potential deal highlights the increasing consolidation in India's hospital sector, driven by significant financial investor activity.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/OEvLf6z
via IFTTT

Read More

India’s heart-risk score in diabetes: Why every Indian must pay attention - A World Heart Month special

In India, individuals with diabetes face a significant risk of cardiovascular disease, necessitating proactive heart health management. Tools like the IDRS and QRISK3 Score help assess this risk, especially crucial given the early onset of heart disease in Indians. Vigilance through regular check-ups, lifestyle adjustments, and awareness during World Heart Month can significantly improve outcomes.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/LUWedl6
via IFTTT

Read More

Roche Pharma partners with 10 govt hospitals to bolster clinical trial capabilities in India

Roche Pharma collaborates with ten government hospitals. The goal is to improve clinical trial capabilities across India. Nearly 400 professionals receive training based on global standards. This initiative helps bring innovations to India faster. It aligns with priorities to boost government site participation. The Advanced Inclusive Research Site Alliance is now active in India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Na8JtuQ
via IFTTT

Read More

Reckitt has joined hands with PATH-CHRI to Launch Dettol Banega Swasth India - Maternal and Child Health Tech Accelerator.

Reckitt, in collaboration with PATH-CHRI, has launched an accelerator to drive innovation in maternal and child health. Centred on the first 1,000 days of life, the initiative aims to improve outcomes and strengthen India’s progress toward Viksit Bharat @2047.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/F7oCRBr
via IFTTT

Read More

Why Indians skip the flu vaccine despite risks

In India, the quadrivalent influenza vaccine (QIV) faces low uptake due to limited awareness and high costs, despite being recommended for vulnerable groups. While global guidelines promote annual flu shots, India's lack of inclusion in the Universal Immunization Programme contributes to poor vaccination rates. Experts emphasize that yearly vaccination is necessary, although not foolproof, to mitigate flu severity and complications.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/t9xN64T
via IFTTT

Read More

Creador to buy 7% stake in pharma company La Renon

Creador, a Kuala Lumpur-based private equity firm, is set to acquire a 7% stake in La Renon Healthcare for ₹800 crore, valuing the Indian pharmaceutical company at nearly ₹11,000 crore. The transaction involves a partial stake dilution by the promoter family and Peak XV Partners.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/SIXkJNM
via IFTTT

Read More

Pharma exporters seek rollback of rule banning export of India-only drugs

A new regulation by India's drug authority, restricting the export of pharmaceuticals labeled "For sale in India only," is causing significant losses to exporters, estimated at $500 million, and limiting access to affordable medicines for patients abroad.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/kKhdya9
via IFTTT

Read More

Cupid announces strategic investment in fragrance brand Mansam

Cupid Ltd, an Indian healthcare products manufacturer, has signed a term sheet to acquire a strategic stake in Mansam, a Saudi Arabian luxury fragrance brand. The investment, facilitated through a fund managed by GII Investment Management Limited, aims to expand Cupid's international presence and tap into new consumer-driven markets.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/FE9vkby
via IFTTT

Read More

Biocon inaugurates first manufacturing facility in US

Biocon Ltd has inaugurated its first US manufacturing facility in Cranbury, New Jersey, operated by its subsidiary, Biocon Generics Inc. Following the acquisition of the Oral Solid Dosage facility from Eywa Pharma Inc in 2023, Biocon invested over USD 30 million to establish the plant.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/r8AKiHu
via IFTTT

Read More

Dr Reddy's inks pact with Johnson & Johnson to acquire vertigo treatment brand

Dr. Reddy's Laboratories has finalized its acquisition of the Stugeron brand from Johnson & Johnson, encompassing EMEA regions, India, and Vietnam. This strategic move allows Dr. Reddy's to broaden its presence in the anti-vertigo market and reinforce its Central Nervous System portfolio. The company aims to extend Stugeron's reach across 18 key markets, aligning with its goal of reaching 1.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ipQhes9
via IFTTT

Read More

Delhi HC stops drug body from taking action against IndiaMart

The Delhi High Court has temporarily blocked the CDSCO from pursuing criminal action against IndiaMart for allegedly listing unapproved medicines. This decision follows complaints regarding the online marketplace listing drugs like Crysvita, Oxbryta, and Jynneos, which are not approved for sale in India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/nzouJ3S
via IFTTT

Read More

Indian hospitals to raise IT innovation spend by 25% in 3 years: Report

Indian hospitals are poised to significantly increase their IT innovation spending, with a large portion of healthcare providers already dedicating a substantial part of their IT budgets to digital advancements. The focus will be on enhancing patient experience, improving clinical outcomes through technology, and enabling data-driven decision-making.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2npRztj
via IFTTT

Read More

WHO adds popular weight-loss drugs to essential medicines list

The World Health Organization has included Semaglutide and Tirzepatide, popular weight-loss drugs, in its Model List of Essential Medicines. This decision could significantly lower the prices of these medications in countries like India, where obesity rates have surged. The WHO aims to improve access and health outcomes by prioritizing those in need and encouraging generic competition.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/B7hnD36
via IFTTT

Read More

Medicines may soon come with braille labels, audio QR codes

India's drug regulatory authority is exploring the addition of braille cards and voice-assisted QR codes on medicine strips to improve accessibility for visually impaired individuals. This initiative follows representations highlighting the difficulties faced by blind individuals in identifying medicines.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/u7VMezX
via IFTTT

Read More

Indian pharma sector needs price hikes, site and IP transfers to tackle US tariff uncertainty: Report

A Systematix Research report indicates the Indian pharmaceutical industry is navigating uncertainty due to US tariffs, necessitating price increases, site transfers, and IP transfers. While raw material prices stabilize and companies explore new growth avenues, first quarter earnings were weak, with margin pressures in the US market. Firms cautiously evaluate inorganic growth and focus on OTC platforms amid these challenges.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ONbHWxd
via IFTTT

Read More

The missed window: Why half of India’s people with diabetes learn too late

Many Indians unknowingly live with diabetes, missing the crucial early detection window. This delay, often due to subtle symptoms and lifestyle factors, leads to severe complications like kidney damage and heart issues. Early screening, awareness of risk factors, and regular check-ups are vital to managing diabetes and preventing long-term health problems.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/c1nQTlv
via IFTTT

Read More

Health experts alarmed by GST cut on beedis, demand uniform taxation

Health experts have criticised the government’s move to cut GST on beedis from 28% to 18% while keeping other tobacco products at 40%. They warned cheaper beedis, widely used by poor communities, could worsen India’s tobacco burden. Doctors stressed beedis are as harmful as cigarettes, urging uniform high taxes to curb use, protect vulnerable groups, and reduce health costs.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/oL06EuC
via IFTTT

Read More

AstraZeneca to invest Rs 176 cr to expand GITC in Chennai

AstraZeneca is investing Rs 176 crore to expand its Global Innovation & Technology Centre in Chennai, marking its third investment in India in two years. This expansion will enhance the center's capabilities in AI, data analytics, and machine learning, supporting the development of next-generation medicines and digital healthcare solutions.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/aDime8O
via IFTTT

Read More

USFDA issues Form 483 with 8 observations to Aurobindo's Telangana unit

Aurobindo Pharma faces scrutiny. The US FDA inspected its Bachupally, Telangana plant. The inspection occurred between August 25 and September 5. Following the inspection, the US FDA issued a Form 483. The form contained eight observations. Aurobindo Pharma stated the observations are procedural. The company plans to respond to the US FDA within the given timeframe.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/kXtOaJq
via IFTTT

Read More

Glenmark initiates multi-nation Phase 3 clinical trial for lung cancer drug

Glenmark Pharmaceuticals has commenced a Phase 3 clinical trial across multiple countries, including India, Russia, Brazil, and Mexico, for Envafolimab, a novel drug targeting third-stage non-small cell lung cancer (NSCLC). The trial aims to evaluate the drug's efficacy, safety, and other key parameters in NSCLC patients.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/WKbNkqL
via IFTTT

Read More

Type 2 diabetes triggering heart attacks in the 30s: Why India’s youth are at risk?

Type 2 diabetes is increasingly affecting young Indians, accelerating heart disease risks due to factors like genetics, visceral fat, and unhealthy lifestyles. Modern diets high in fats and sugars, coupled with sedentary habits and mental stress, significantly contribute to early heart attacks.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Xi5b1HV
via IFTTT

Read More

Pharma companies cheer lower drug prices, API tax gap stirs worry

Goods and Services Tax reforms are expected to reduce medicine prices in India. Experts say this will benefit patients and businesses. However, concerns exist regarding the higher tax rate on Active Pharmaceutical Ingredients. This could increase working capital pressure, especially for smaller companies. Provisional refunds may help mitigate these challenges. The government has reduced GST on several expensive medicines.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/rJcQTk6
via IFTTT

Read More

GST cut on drugs, medical devices to provide relief to patients: Industry players

The government is reducing GST on medicines and medical devices. Lifesaving drugs are exempt. This action will help patients and families. It will also make healthcare more affordable. Sudarshan Jain and Anil Matai welcome the changes. Ameera Shah and Shobana Kamineni also support the move. Himanshu Baid says it will improve access to medical technologies.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/9WnEXcQ
via IFTTT

Read More

Crucial drugs to be more affordable after GST cut

The government has significantly reduced GST rates on 41 highly priced medicines, including those for cancer, rare diseases, and heart conditions, aiming to make healthcare more affordable. Key drugs like Risdiplam and daratumumab will now have zero GST, benefiting patients with spinal muscular atrophy and multiple myeloma.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/T3D0ben
via IFTTT

Read More

Centre set to amend rules to simplify drug testing process

The Indian government is amending drug regulations to expedite the approval process for clinical trials and bioavailability/bioequivalence studies. These changes aim to reduce the statutory processing time for test license applications from 90 to 45 days. By simplifying procedures and reducing the number of license applications, the government anticipates faster drug development and approval, benefiting stakeholders and optimizing resource allocation.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Kijh5TH
via IFTTT

Read More

Alkem's Enzene powers into US with $70 m investment

Enzene Biosciences, an Alkem Labs subsidiary, has inaugurated a new US manufacturing plant. The facility is located in New Jersey. This venture represents a $70 million investment. It aligns with calls to boost local pharma manufacturing. Enzene's technology offers cost-effective drug production. The company currently employs 50 people. Enzene plans to increase its workforce to 200.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/FW6hpHG
via IFTTT

Read More

Singapore-based firm proposes to acquire 25% in Welcure Drugs & Pharma

Welcure Drugs & Pharmaceuticals receives an offer from Telexcell Trade. Telexcell Trade, based in Singapore, plans to acquire a 25 per cent stake. The indicative price is Rs 20 per share. This investment aims to expand Welcure's global presence. The all-cash investment is estimated at Rs 52 crore. Welcure intends to invest in an agro-pharma research lab.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/oVTei6H
via IFTTT

Read More

Lupin gets USFDA nod for generic risperidone extended-release injectable suspension

Lupin Ltd. secured USFDA approval for its generic risperidone extended-release injectable suspension, a treatment for schizophrenia and bipolar disorder. This marks Lupin's first product utilizing Nanomi BV's technology, benefiting from 180-day competitive generic therapies exclusivity. The drug, with estimated annual sales of USD 190 million, expands access to complex injectables for patients globally.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/O5cr3uk
via IFTTT

Read More

Caplin Point arm gets USFDA nod for milrinone lactate in 5 pc dextrose injection

Caplin Point Laboratories' arm, Caplin Steriles, secured USFDA approval for its generic milrinone lactate in 5% dextrose injection. Indicated for acute decompensated heart failure, the injection is a generic version of Sanofi Aventis' PRIMACOR. The US market for this injection reached approximately USD 11 million in sales for the year ending July 2025.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/sRMWo3w
via IFTTT

Read More

Medical device manufacturers allowed to give free samples

Medical device companies in New Delhi can now give doctors free samples. There are rules for this. The sample's price must match what stockists pay. If the company bought the sample, that price counts. Company CEOs must ensure code compliance. Marketing costs must be disclosed yearly. This promotes ethical marketing and benefits both manufacturers and patients in India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/6CKwkI5
via IFTTT

Read More

India eyes Russia, Brazil, Netherlands for pharma export growth as US tariffs concerns linger

India is strategically planning to boost its pharmaceutical exports to Russia, the Netherlands, and Brazil, aiming to reduce reliance on the U.S. market due to tariff concerns. While the U.S. remains a crucial market, India seeks to diversify its export chain and increase market share in these growing regions.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/i1YXg7P
via IFTTT

Read More

Glenmark launches generic cancer treatment drug in US

Glenmark Pharmaceuticals on Tuesday launched Eribulin Mesylate Injection, a generic cancer treatment, in the US through its subsidiary Glenmark Pharmaceuticals Inc., USA. The product, equivalent to Eisai’s Halaven Injection, will begin distribution this month.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/GA9Vtaz
via IFTTT

Read More

Zydus launches VaxiFluTM trivalent influenza vaccine for flu protection in India

Zydus Lifesciences has introduced VaxiFlu, a trivalent influenza vaccine, in India. This vaccine aligns with WHO guidelines. It is for individuals aged six months and above. The vaccine contains updated strains for optimal protection. Flu remains a global health concern. It causes millions of severe illnesses and respiratory deaths annually. VaxiFlu aims to reduce vaccine-preventable diseases, especially in high-risk groups.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/HVIgytb
via IFTTT

Read More

Fortis Healthcare arm inks 15-year lease with RR Lifesciences to expand NCR reach

Fortis Healthcare's subsidiary, International Hospital Limited, has secured a 15-year lease. This agreement with RR Lifesciences Limited allows Fortis to operate and expand its facility in Greater Noida. Fortis will now have complete control over the 200-bed hospital, known as Fortis Hospital Greater Noida. The hospital aims to increase its capacity to approximately 250 beds.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/AhIEa3Z
via IFTTT

Read More

The #WeightofDiabetes iceberg: Why the real burden lies beneath the surface

India faces a significant diabetes crisis, with millions undiagnosed, increasing the risk of heart disease. Early detection through screening and lifestyle changes like diet and exercise are crucial. Community programs and modern treatments offer hope for managing diabetes and improving long-term health outcomes, reducing the economic and health burden.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/8tuywW5
via IFTTT

Read More

Govt launches advanced biomanufacturing hubs to boost bioeconomy, innovation

India has launched a network of advanced biomanufacturing hubs to boost its bioeconomy and drive innovation across sectors like health, agriculture and energy. This initiative, under the BioE3 Policy, provides state-of-the-art infrastructure and expertise to startups and researchers. India aims to achieve a USD 300 billion bioeconomy by 2030, positioning itself as a global leader in biotechnology.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/dE9MpFX
via IFTTT

Read More

Novo Nordisk ties up with Apollo Clinics for obesity management initiative

Novo Nordisk partners with Apollo Clinics to tackle obesity in India. The collaboration introduces a comprehensive obesity management programme across Indian cities. This initiative aims to provide structured care through multiple levels. The partnership focuses on equipping healthcare professionals with tools and support. The goal is to deliver personalized, evidence-based interventions.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Ok3qBwd
via IFTTT

Read More

Pharmaceutical industry seeks relief from rate inversion

The pharmaceutical industry in India anticipates potential relief from Goods and Services Tax inversion. Discussions between companies and the government suggest a favourable resolution within upcoming GST reforms. The current tax structure creates working capital issues, especially for MSMEs. Delayed refunds force MSMEs to take loans. Exporters face strain paying upfront taxes on APIs.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/tmQ3Cg8
via IFTTT

Read More

Indian hospitals battle central line infections linked to mismanagement of tubes used for administering medicines and fluids

A seven-year Indian study reveals alarmingly high rates of bloodstream infections from central lines, especially in newborns, with a 40% mortality rate within two weeks. The infection rate is significantly higher than in the US, exacerbated by antibiotic resistance and overwhelmed ICUs during COVID-19. Experts emphasize the need for improved monitoring, infection control, and staffing to reduce these preventable infections.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/7DMYBQw
via IFTTT

Read More

Repurposed anti-cholesterol drug statin can stymie cancer, help support treatment, say researchers

Statins, drugs for high cholesterol, show promise in slowing colorectal cancer growth. Researchers at Shiv Nadar University and IISER Pune found statins target key pathways in cancer cells. The study suggests statins could be repurposed for cancer treatment. More trials are needed to confirm these findings.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/L8WiavN
via IFTTT

Read More

Scientists find why ultra-processed diets make you gain fat even without extra calories: Study

A recent study reveals that consuming ultra-processed foods leads to greater weight gain compared to minimally processed diets, even with the same calorie intake. The research, involving healthy young men, also found that ultra-processed diets disrupt hormone levels and introduce pollutants linked to decreased sperm quality. These findings underscore the detrimental impact of processed foods on metabolic and reproductive health.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/r3YSEcZ
via IFTTT

Read More

Zydus Saroglitazar shows positive Phase 3 results in rare liver disease PBC, US filing planned in 2026

Zydus Therapeutics reveals encouraging outcomes from Saroglitazar's clinical trial. The drug targets Primary Biliary Cholangitis. The EPICS-III trial demonstrates improved liver function in patients. These patients did not respond to standard treatment. Zydus plans to seek US regulatory approval in early 2026. Saroglitazar is a novel treatment option. It addresses bile acid toxicity and liver inflammation.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/vjFK0CD
via IFTTT

Read More

Murae Organisor plans to boost agro-sector presence under Rs 80-cr investment strategy

Murae Organisor Ltd is set to bolster its agro-sector presence with an Rs 80 crore investment in R&D and infrastructure. The plan includes establishing an Agro R&D Laboratory, developing processing and packaging infrastructure, and implementing digital traceability systems. This strategic move follows the company's proposed qualified institutional placement (QIP) of up to Rs 80 crore.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Fk4UOZS
via IFTTT

Read More

IHH Healthcare to add 2,000 beds in India by 2028

IHH Healthcare plans to expand its presence in India by adding approximately 2,000 new beds by 2028. This expansion will be facilitated through its subsidiaries, Fortis Healthcare and Gleneagles Healthcare, which currently operate 35 hospitals with over 5,000 beds across 11 states.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/QxuECrd
via IFTTT

Read More

FDA approves updated COVID-19 shots but limits access for some kids and adults

U.S. regulators have approved updated COVID-19 shots from Pfizer, Moderna, and Novavax, but access is now limited for younger adults and children to those with high-risk conditions. Pfizer's vaccine is no longer available for children under 5, while Novavax's shot is restricted to those 12 and older. These changes reflect a shift in U.S.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/4z301L6
via IFTTT

Read More

Catching heart disease in its quietest moments in Type 2 diabetes

Early detection of heart disease in Type 2 diabetes is crucial, as it often develops silently. Advanced tests like high-sensitivity blood work, imaging, and genetic screening can identify hidden risks before symptoms appear. Proactive measures, including lifestyle changes and personalized medication, can significantly reduce cardiovascular complications and improve outcomes.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/6ByGFHL
via IFTTT

Read More

Drug, medtech companies fear GST changes may squeeze funds

Pharma and medtech sectors are concerned about upcoming Goods and Services Tax changes. They anticipate higher operating costs and working capital issues. Rajiv Nath suggests a balanced GST approach for equipment and consumables. Federation of Pharma Entrepreneurs urges lower GST on APIs to avoid inverted duty structure. MSMEs fear blocked funds and slowed growth due to tax imbalances.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ZTCn0xy
via IFTTT

Read More

Dr Reddy's expects new GST framework to address critical issues impacting pharma sector

Dr Reddy's Laboratories anticipates that the new Goods and Services Tax structure will address existing challenges. It will also create a rationalised tax framework for the pharmaceutical sector. The Association of Indian Medical Device Industry seeks to retain 12 percent GST for most consumables. It also wants 5 percent rate on costly equipment.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/LN2v7zg
via IFTTT

Read More

Dr Reddy's launches novel drug for chronic constipation management

Dr Reddy's Laboratories has introduced Colozo, a generic drug for chronic constipation in India. This medication, Linaclotide, is approved by the USFDA. It addresses chronic idiopathic constipation and irritable bowel syndrome. This launch strengthens Dr Reddy's gastrointestinal segment. It follows the introduction of BixiBat in India last year. The company aims to improve patient care and serve 1.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/xGuUVvT
via IFTTT

Read More

Sampre Nutrition inks 3-year manufacturing pact with Rama Exports for nutraceuticals

Sampre Nutrition has partnered with Rama Exports in a manufacturing agreement to produce nutraceuticals and food products. Sampre Nutrition will handle manufacturing, supply, quality assurance, and packaging, while Rama Exports will purchase the finished goods over a three-year contract. This agreement is projected to generate Rs 15 crore in business, boosting Sampre Nutrition's revenue and strengthening its operations.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/HPuawKj
via IFTTT

Read More

GSK enters into oncology segment; launches therapies for gynaecological cancers

GlaxoSmithKline Pharmaceuticals has entered the oncology segment in India, introducing Jemperli and Zejula for gynaecological cancers. These therapies address unmet needs in endometrial and ovarian cancer treatment, with incidence projected to rise significantly by 2045. Jemperli offers targeted immunotherapy for advanced endometrial cancer, while Zejula provides first-line maintenance therapy for advanced ovarian cancer.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/UfkMqiF
via IFTTT

Read More

From Clinic to Crisis: How Poor Follow-Up Fuels the Type 2 Diabetes Epidemic

Many individuals with diabetes in India are unaware of their condition, leading to missed opportunities for early treatment and increased health risks. Regular follow-up appointments are crucial for monitoring progress, identifying early warning signs, and adjusting treatment plans to prevent complications. Skipping these check-ups can result in silent damage to vital organs and faster progression of the disease.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/P2zhxni
via IFTTT

Read More

India's healthcare chains set their hearts on foreign patients

Indian healthcare providers are aggressively pursuing a larger share of the medical tourism market, fueled by a significant increase in foreign patients seeking treatment. Tourist arrivals for medical reasons have surged, with hospitals now attracting patients from Europe and the UK, in addition to traditional markets.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/aplvDgO
via IFTTT

Read More

Global PE firms tighten grip on India’s $80-billion hospital sector

India's private hospital sector has seen a significant shift towards ownership by global private equity firms in the last five years, especially after the Covid-19 pandemic. This trend is reshaping the healthcare market, attracting investments from entities like Temasek, TPG, and KKR.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/HKgSMQC
via IFTTT

Read More

IMA warns of misuse, mis-prescription of new weight-loss drugs, such as Wegovy and Mounjaro

The Indian Medical Association is raising concerns about the misuse of weight-loss drugs like Wegovy and Mounjaro, urging stricter prescription controls. They plan to petition the health ministry and drug regulator, advocating for prescriptions to be limited to certified endocrinologists or diabetologists. Rampant prescriptions by cosmetologists and other non-specialists are fueling concerns about potential side effects and improper usage.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/UcrkMaY
via IFTTT

Read More

Novo Nordisk warns patients after theft of weight-loss, diabetes drugs

Novo Nordisk urges customers to purchase medications solely from authorized pharmacies with valid prescriptions after a theft of products, including semaglutide and insulin treatments, during transportation. The company is cooperating with authorities and reinforcing supply chain safeguards. CDSCO has issued an alert, advising caution and vigilance in procuring Novo Nordisk products from trusted sources due to potential compromised quality.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/vU71Iaq
via IFTTT

Read More

CDSCO issues alert on Novo drugs after reported theft

The CDSCO has alerted healthcare professionals and consumers about stolen Novo Nordisk products, including semaglutide and insulin injectables. These products, requiring specific temperature control (2-8°C), may be compromised if improperly stored. The regulator has instructed state drug control offices to monitor the market and take action under the Drugs and Cosmetics Act, 1940, while police investigate the theft during transit.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/GRFfUEp
via IFTTT

Read More

Substantial cancer drugs beyond ambit of current price control mechanisms: Parliamentary panel

A parliamentary panel has urged for broader price controls on cancer drugs, noting that many remain unaffordable. The committee recommends regular market assessments, quality monitoring of generic medicines, and enhanced domestic research. Streamlining regulatory pathways and fostering public-private collaboration are crucial for improving access to novel therapies.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/vsfilqK
via IFTTT

Read More

Stricter shelf life rule a bitter pill to swallow for pharma companies

A new regulation by the CDSCO mandates that exported drugs must have at least 60% shelf life remaining, causing significant losses to the Indian pharmaceutical industry. Manufacturers are now forced to destroy stocks to comply with this rule. The industry is urging for a revision, citing unnecessary losses and questioning the need when importing countries permit shorter shelf lives.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/dGhcLye
via IFTTT

Read More

Drugmaker Novo Nordisk freezes hiring for non-critical jobs

Novo Nordisk, the maker of Wegovy, has initiated a global hiring freeze for non-critical roles amid increasing competition and pressure from Eli Lilly. This decision follows a profit warning that led to a significant drop in market value and the appointment of a new CEO, Mike Doustdar, who is considering cost-saving measures, including potential layoffs.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/RsJVMF5
via IFTTT

Read More

Natco Pharma launches generic drug with 180-day exclusivity in US

Natco Pharma has launched Bosentan tablets, a generic version of Tracleer, in the US for treating pulmonary arterial hypertension in young patients. This launch comes with 180-day exclusivity. Lupin Ltd. is Natco's marketing partner for this product. The drug had estimated sales of USD 10 million in the US for the 12 months ended June this year.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/J5HvGMB
via IFTTT

Read More

When the heart and sugar collide: The overlooked risk in Type 2 diabetes

Type 2 diabetes significantly elevates the risk of heart disease due to high blood sugar damaging arteries, leading to plaque buildup and reduced blood flow. Recognizing subtle symptoms like chest pain or shortness of breath is crucial for early intervention. Simple lifestyle adjustments, including a balanced diet, regular exercise, and stress management, can significantly protect heart health.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/tNAOYfd
via IFTTT

Read More

Aurobindo Pharma closing in on $5.5b Zentiva buyout

Largest Indian pharma M&A in final lap; PE firm GTCR only other contender. A portfolio company of Advent International, Zentiva will significantly boost Aurobindo’s European footprint.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Sa0FGJC
via IFTTT

Read More

Indian drugmakers seek exemption for generics from US supplies probe

Indian pharmaceutical industry representatives met with Union Commerce Minister Piyush Goyal. They requested the US government to exclude generic drugs from its investigation into pharmaceutical imports. The probe, under Section 232, raises concerns about supply chain disruptions. This discussion occurs amidst India-US trade negotiations and potential US tariffs.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/J3tBKf9
via IFTTT

Read More

Glenmark, Alembic Pharma, Sun Pharma recall products in US: USFDA

Glenmark, Alembic Pharmaceuticals, and Sun Pharma are recalling various products in the US due to manufacturing issues, according to the USFDA. Glenmark is recalling Carvedilol tablets due to nitrosamine impurity and Theophylline tablets for failed dissolution. Alembic is recalling Doxepin capsules for a similar impurity issue, while Sun Pharma recalls Spironolactone tablets due to aluminum contamination.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/82y5NSr
via IFTTT

Read More

Alembic gets USFDA nod for generic drug for skin condition

Alembic Pharmaceuticals has secured USFDA approval for its generic Tretinoin Cream USP (0.025%), a treatment for acne vulgaris. This ANDA is therapeutically equivalent to Bausch Health US, LLC's Retin-A Cream. The market size for Tretinoin cream USP (0.025%) is estimated at USD 94 million for the twelve months ending June 2025.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/rQjfEAB
via IFTTT

Read More

Aurobindo Pharma expects China plant to break even at EBITDA level this year

Aurobindo Pharma anticipates its China facility will achieve break-even by Q3 FY26. Production is ramping up after commencing operations in November 2024. The company invested USD 145 million in the facility. Aurobindo Pharma also invested in US facilities and plans to file for products in the US and Europe.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Hs24qbj
via IFTTT

Read More

Food Chained: How weight-loss drugs are changing India’s eating habits and forcing restaurants to take note

New diabetes and obesity drugs, like Mounjaro and Ozempic, are changing people's relationships with food. While these drugs help control diabetes and promote weight loss by altering taste and reducing hunger, some users experience a loss of enjoyment in eating and even develop food anxieties.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/qipXT2j
via IFTTT

Read More

Max Healthcare to nearly double capacity to 9,500 beds by 2028 after strong quarterly growth

Max Healthcare Institute aims to nearly double its bed capacity to 9,500 by 2028 through brownfield and greenfield expansions, following a 35% increase to 5,000 beds last year. The company reported a 27% jump in first-quarter revenue to Rs 2,574 crore and a 17% rise in net profit to Rs 345 crore, driven by higher occupancy and international patient revenue.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/tES5J9n
via IFTTT

Read More

Cohance Lifesciences announces $10 million investment in US-based arm

Cohance Lifesciences is investing USD 10 million to expand bioconjugation capabilities at its US subsidiary, NJ Bio, enhancing its ADC solutions. This investment aims to support innovators from early development through late-phase clinical supply. Additionally, Cohance is investing Rs 23 crore in a new oligonucleotide building block manufacturing facility in Hyderabad, part of a broader capacity expansion program.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/G6moSWY
via IFTTT

Read More

From burden to breakthrough: Reimagining the #WeightofDiabetes through meaningful conversations with your doctor

Effectively managing type 2 diabetes involves more than just medication; it requires open communication with healthcare providers to address weight, heart health, and emotional well-being. Proactive conversations can clarify confusion, uncover barriers, and empower individuals to take charge of their health, preventing crises and promoting resilience through personalized care and support.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/n6QNrjO
via IFTTT

Read More

Intas Pharma completes acquisition of UDENYCA biosimilar for $558 million

Intas Pharma finalized its acquisition of UDENYCA, a biosimilar to Neulasta, from Coherus Life Sciences for $558 million in December 2024. This acquisition strengthens Intas's position as a global leader in pegfilgrastim. Accord BioPharma, Intas's U.S. specialty business, will continue commercializing UDENYCA to reduce infection risk in cancer patients undergoing myelosuppressive chemotherapy.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/tpuhbM4
via IFTTT

Read More

Lupin ties up with Sandoz to commercialise biosimilar product

Lupin has partnered with Sandoz Group AG to commercialize its biosimilar ranibizumab across multiple regions, with Sandoz handling commercialization in the EU (excluding Germany), Switzerland, Norway, Australia, Hong Kong, Vietnam, and Malaysia. Lupin will manufacture the product and manage regulatory submissions. Sandoz also gains exclusive rights for commercialization in Canada.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/9LHTCSq
via IFTTT

Read More

Chemists seek ban on quick commerce sale of prescription drugs

The All India Organisation of Chemists and Druggists (AIOCD) has appealed to Amit Shah. They want immediate action against e-pharmacies and quick commerce platforms. These platforms are selling prescription medicines online. AIOCD says this poses a public health risk. They are concerned about drug abuse, especially among young people. AIOCD also highlights the issue of ghost prescriptions.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/XILAdwq
via IFTTT

Read More

Asia Healthcare Holdings to invest Rs 400 crore in Asian Institute of Nephrology and Urology to double hospital network

Asia Healthcare Holdings will invest Rs 400 crore in Asian Institute of Nephrology and Urology. The investment will occur over the next 4-5 years. AINU plans to expand by opening 13 hospitals in Tier 2 cities. This expansion includes cities like Patna and Bhubaneshwar. The total investment will reach Rs 1,000 crore by FY30.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/FypJzrY
via IFTTT

Read More

Pfizer launches next-gen vaccine for pneumococcal disease

Pfizer has introduced its 20-valent pneumococcal conjugate vaccine (PCV20) for adults in India, offering protection against 20 serotypes responsible for a majority of pneumococcal diseases. This single-dose vaccine provides timely and proactive protection for all adults, including those with chronic conditions, potentially eliminating the need for a second dose.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/T8l6hCc
via IFTTT

Read More

Welcure Drugs & Pharma board to consider share split, bonus issue this month

Welcure Drugs & Pharmaceuticals is set to consider a stock split of 1:10 and a bonus issue of 1:1 in its upcoming board meeting on August 22. This decision follows strong financial results in Q1 FY26, with revenue from operations reaching Rs 299.91 crore and net profit surging to Rs 23.29 crore.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/MIrfW2R
via IFTTT

Read More

Zydus Lifesciences gets USFDA approval for angina, high blood pressure drug

Zydus Lifesciences has secured USFDA approval to market Diltiazem Hydrochloride tablets, used for treating angina and high blood pressure, in strengths of 30 mg, 60 mg, 90 mg, and 120 mg. The medication, a calcium-channel blocker, relaxes blood vessels, easing the heart's workload and improving blood flow.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/4CdspvA
via IFTTT

Read More

Retinal disorders a public health crisis, need immediate prioritisation, say experts

Mission Vision, a public health initiative, has launched in India to combat the escalating crisis of vision loss due to Diabetic Retinopathy. The initiative aims to increase awareness, improve screening and treatment access, and integrate eye care into routine diabetes management.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/UecTf9s
via IFTTT

Read More

Managing diabetes in a country obsessed with quick fixes: A scientific perspective

Diabetes management faces challenges due to patients' preference for quick fixes over sustainable lifestyle changes. These shortcuts, like extra medication or unproven supplements, offer temporary relief but neglect long-term disease control. Shifting mindsets requires holistic approaches, personalized support, and collaborative healthcare to promote lasting healthy habits and prevent complications.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/wmz1MyF
via IFTTT

Read More

Govt gives BIS exemption to parts used in medical devices for now

The steel ministry has temporarily suspended its notification requiring Indian standards compliance for raw materials used in medical device manufacturing, offering relief to the industry. They will issue no-objection certificates for importing special stainless steel grades and allow foreign suppliers six months to obtain Bureau of Indian Standards registration.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/xAzXsHv
via IFTTT

Read More

Biocon sees GLP-1 weight-loss therapy as a future growth driver

Biocon will strengthen its insulin business while advancing in GLP-1 therapies, with semaglutide in Phase-III trials and a planned 2027 India launch. CEO Shreehas Tambe said both portfolios are complementary. Biocon aims to leverage its insulin experience for GLP-1 success, following US FDA approval for insulin aspart and India approval for liraglutide. External risks remain a key concern.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/dw4pEIK
via IFTTT

Read More

Medical device firms sound the alarm over new steel standards

Earlier, foreign suppliers only needed BIS certification for finished steel products. Under the new rule, materials like hot rolled steel, ingots manufactured by other countries for Indian buyers will have to get BIS certification. The manufacturers have written to the ministry of steel seeking exemption for the import of stainless steel capillary without BIS certification.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/FurWfSZ
via IFTTT

Read More

Weight-loss drug Mounjaro crosses Rs 100 crore sales in 4 months

The drug clocked Rs 47-crore sales in July, double its June figure, according to data from prescriptions tracker PharmaTrac. If this month-on-month doubling of sales continues, Mounjaro’s revenue could cross Rs 500 crore by March, experts estimate.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/xLPVHcg
via IFTTT

Read More

Novo Nordisk's Wegovy, Mounjaro sales in India double on month in July

Sales of Novo Nordisk's Wegovy and Eli Lilly's Mounjaro in India doubled in July, according to Pharmarack data. Wegovy, launched in June, saw sales more than double to 5,000 units, while Mounjaro sales also doubled to 157,000 units. Mounjaro's sales have soared 15 times since its March launch in India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/AhPSKaq
via IFTTT

Read More

Executive order by US administration excludes Pharma sector from immediate tariff imposition: Indian Pharmaceutical Alliance

The Indian pharmaceutical sector has been excluded from immediate US tariff hikes due to the importance of generic medicines for affordable healthcare in the United States. This follows President Trump's imposition of a 25% tariff on India over Russian oil purchases, raising the total tariff to 50%.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/bkQCuVn
via IFTTT

Read More

Indian pharma on alert as US mulls higher drug tariffs

Indian drug makers are assessing the potential consequences of additional tariffs imposed by the US in response to India's oil purchases from Russia. While previous tariffs spared pharmaceuticals, uncertainty prevails due to frequent policy changes. Companies are exploring mitigation strategies like price adjustments and technology transfer to the US, anticipating manageable impacts on medicine access.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/JTxi1wE
via IFTTT

Read More

More heart attacks in diabetes? Here’s what you should know

Type 2 diabetes elevates the risk of heart issues, but advancements offer hope. New treatments not only manage blood sugar but also promote weight loss, lower blood pressure, and improve cholesterol, reducing heart-related hospitalizations. Addressing obesity is crucial, and consulting a doctor about comprehensive diabetes and heart health management is recommended.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/GwPz60k
via IFTTT

Read More

Indian generics wave next year set to sink obesity drug price

Leading Indian drugmakers are preparing to launch generic versions of semaglutide by March. Analysts predict a significant price drop, potentially up to 80%. This will make the drug more accessible to obese and diabetes patients. The domestic weight-loss drug market is expected to grow substantially. Semaglutide patent expiry will trigger price erosion and increased adoption.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/l0384zN
via IFTTT

Read More

Eris Lifesciences eyes ‘good’ share in semaglutide generics, says COO

Eris Lifesciences plans to lead in generic semaglutide drugs. The patent for Novo Nordisk's drug expires in India in March 2026. Eris aims for a significant market share. Several Indian drugmakers are also preparing to launch generic versions. Eris has experience with diabetes drugs. The company hopes to leverage its existing portfolio. It includes orals, insulin, and GLP-1.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/0wQPGY2
via IFTTT

Read More

Pharma tariffs may go as high as 250%, says Trump

U.S. President Donald Trump said new tariffs on imported pharmaceuticals will start small but could rise to 250% within 18 months to boost domestic production. He also plans to announce fresh duties on foreign semiconductors, aiming to reduce U.S. reliance on overseas supply chains.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/xS1FQAT
via IFTTT

Read More

Mind, muscle, and metabolism: The power of holistic diabetes management

Managing diabetes holistically involves more than just blood sugar control, encompassing lifestyle factors like diet, exercise, and mental well-being. Small changes, such as increasing fiber intake and regular walking, can significantly impact health. Understanding hormones like GLP-1 and insulin, along with addressing stress and sleep, are crucial for comprehensive diabetes care and improved overall well-being.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/THnDtI9
via IFTTT

Read More

Corner Office Conversation with The New Leaders of Indian Pharma

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/yagzUpd
via IFTTT

Read More

Manipal Hospitals seeks CCI nod to acquire Sahyadri Hospitals for about Rs 6,400 cr

Manipal Hospitals is planning to acquire Sahyadri Hospitals. The deal is estimated at around Rs 6,400 crore. Manipal has sought approval from the Competition Commission of India. This acquisition will significantly expand Manipal's presence in western India. It will also increase Manipal's total bed count to approximately 12,000. Sahyadri Hospitals currently operates 11 hospitals in Maharashtra.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Iv06Knp
via IFTTT

Read More

70% enrolment of participants for Phase III clinical trial of dengue vaccine completed: Centre

India achieves a milestone in dengue prevention. The DengiAll vaccine trial sees 70% participant enrollment. ICMR leads the multi-center study across 20 Indian sites. The budget is approximately Rs 1.3 to 1.5 crore per site. Dengue cases are rising, with over 5 lakh confirmed in 2024. The government monitors outbreaks and provides support to states.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ZYMrA1o
via IFTTT

Read More

Apollo entities seek CCI nod for recast plan

Apollo Group is seeking CCI's approval for a restructuring plan to list its omnichannel pharmacy and digital health businesses within 18-21 months. This involves merging Apollo's digital platforms and Keimed into Apollo Healthtech, creating a major player with ₹16,300 crore in FY25 revenues. Subsequently, Apollo Healthtech will acquire a 74.5% stake in Apollo Medicals.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ZWrCon5
via IFTTT

Read More

Sun Pharmaceutical says it won't expand US manufacturing base amid tariff concerns

Sun Pharmaceutical, India's largest drug maker, is not planning to expand its manufacturing base in the US, citing sufficient existing capacity. The company remains watchful of potential reciprocal tariffs, though pharmaceuticals are currently exempt pending a US investigation.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/W67FCgn
via IFTTT

Read More

Pharma industry to outdo India Inc in 2025 pay hike: Study

Pharma companies in India are projected to offer an average salary increment of 9.6% in 2025, slightly lower than the previous year but still surpassing the 8.8% average for corporate India. Emerging roles like regen medicine researcher and digital health programme officer are expected to receive even higher increments.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ucdsChJ
via IFTTT

Read More

Obesity drugs gain weight in labs: Several clinical trials by big and small pharma cos underway

Driven by the success of Wegovy and Mounjaro, numerous pharma companies are developing anti-obesity drugs, with over 170 in various stages. While giants like Novartis and GSK are cautious, Eli Lilly and Novo Nordisk lead the race. Research expands beyond GLP-1 targets, exploring oral options and addressing conditions like MASH and CVD.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/j0HGQFk
via IFTTT

Read More

Medtech firms flag inflated MRPs on imported devices

Indian medical device manufacturers have raised concerns that private hospitals and retailers are favoring imported devices with inflated prices or missing MRPs to gain higher margins. This practice disadvantages domestic manufacturers, who offer similar products at lower costs. The industry has urged the government to investigate unfair trade practices and duty evasion related to excessive MRPs on imported devices.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Mci8hzB
via IFTTT

Read More

Pharma exporters expect Trump to act benevolently to them

Indian drug makers, heavily reliant on the US market, face potential challenges due to President Trump's proposed 25% reciprocal tariff on imports from India. While analysts anticipate a possible exemption or reduced tariff for the pharma sector, companies are preparing to pass on costs to customers.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/qjW5TRB
via IFTTT

Read More

650 private hospitals in Haryana to withdraw from Ayushman Bharat scheme over unpaid dues

Around 650 private hospitals in Haryana are threatening to halt Ayushman Bharat services from August 7 due to ₹500 crore in pending reimbursements. The Indian Medical Association (IMA) Haryana unit reports that hospitals have received only a fraction of their dues since March, creating a severe financial strain.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/1UVluDZ
via IFTTT

Read More

Jashvik Capital acquires Rs 400 crore stake in Marg ERP

Jashvik Capital has invested Rs. 400 crore for an undisclosed stake in Marg ERP, a company serving over 500,000 subscribers across multiple industries. Marg ERP's founders recently bought back a 49% stake from API Holdings. Jashvik Capital aims to leverage its expertise to help Marg ERP become a global healthcare SaaS leader.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/GLhYBTW
via IFTTT

Read More

PE funds vie for a majority stake in medical devices maker Sensa Core

Several private equity firms, including KKR and TPG, are considering acquiring a majority stake in Sensa Core Medical Instrumentation. The deal could value the Indian medical device manufacturer at around $300 million. Sensa Core is a major producer of in-vitro diagnostic analysers. The medical device sector in India is attracting significant investor interest.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/5WiSJbr
via IFTTT

Read More

Understanding the chain reaction of chronic diseases

Chronic diseases often occur together. Diabetes can damage blood vessels, affecting the heart and kidneys. Managing blood sugar and weight helps. The body produces hormones like insulin and GLP-1 to regulate blood sugar. Consult your doctor to understand the connections between your conditions. Holistic care improves overall health. Small steps can lead to big improvements.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/9QXZz63
via IFTTT

Read More

Monitor presence of potentially carcinogenic chemical in Ranitidine: DCGI to drug controllers

The DCGI has directed state and UT drug controllers to monitor levels of the potentially carcinogenic NDMA in Ranitidine, an antacid. This action follows concerns about NDMA impurity and recommendations from the Drugs Technical Advisory Board (DTAB). Manufacturers are urged to take risk-based measures, including shelf-life reduction, while ICMR considers a safety study.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/nXCUWMv
via IFTTT

Read More

Maker of GLP1 pens scales up for generic debuts

As weight-loss drug sales surge with semaglutide's patent expiration, Gujarat's Shaily Engineering Plastics, an injector pen manufacturer, anticipates significant growth. Its stock has nearly doubled, and the company is doubling its production capacity to 80-85 million pens by fiscal year-end to meet rising domestic and export demands.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/yGJ7CbR
via IFTTT

Read More

Type 2 Diabetes diet plan: What to eat in a day

Struggling to manage type 2 diabetes through diet? Here’s a simple, balanced full-day eating guide with diabetic-friendly foods to stabilize blood sugar and boost energy levels naturally.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/u5d6SNx
via IFTTT

Read More

Alembic Pharmaceuticals gets USFDA nod for generic Carbamazepine tablets

Alembic Pharmaceuticals has received final approval from the USFDA for its generic Carbamazepine extended-release tablets (100 mg, 200 mg, and 400 mg), used to treat seizures and nerve pain. The product is a generic version of Novartis’ Tegretol-XR. According to IQVIA, the U.S. market for these tablets is estimated at $71 million for the 12 months ending March 2025.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/YlgnM0c
via IFTTT

Read More

Cheaper cancer care therapy earns big bucks for pharma company

ImmunoAct, an Indian cell and gene therapy company, has achieved profitability in its first full year, generating ₹62 crore in revenue and ₹12 crore in profit before tax in FY25. Its NexCAR19, an affordable CAR-T therapy, has been administered to over 350 patients across India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/7auwHQG
via IFTTT

Read More

Does green coffee really help you lose weight? Here's the truth

Green coffee has become popular as a natural weight loss supplement, but how effective is it really? Here's a detailed look.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Cmbn25G
via IFTTT

Read More

AIOCD demands strict action against illegal e-pharmacies; raises alarm over inaction by SLAs

The All-India Organisation of Chemists and Druggists raises concerns. It highlights the illegal operation of online pharmacies. These pharmacies violate drug regulations. AIOCD urges the government to take immediate action. They want a crackdown on unlicensed e-pharmacies. The organization calls for the withdrawal of certain regulations. These regulations are being misused. AIOCD emphasizes the need to protect public health.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/8ywhK2O
via IFTTT

Read More

Sun Pharma, Lupin, Dr Reddy's recall products in US market due to manufacturing issues

Three major Indian pharmaceutical companies are recalling drugs in the United States. Sun Pharma is recalling Lisdexamfetamine capsules due to failed dissolution specifications. Lupin is recalling Lisinopril and Hydrochlorothiazide tablets because of product mix-up with Atazanavir and Ritonavir tablets. Dr Reddy's Laboratories is recalling Omeprazole capsules due to the presence of foreign Divalproex Sodium tablets.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/DZBhVbc
via IFTTT

Read More

Non-alcoholic fatty liver disease: An acute menace and a silent killer

Fatty liver disease is a growing health crisis due to obesity and poor lifestyles. Many individuals are unaware until imaging reveals the issue. A recent screening showed 65% had fatty liver, with normal enzyme levels in many. Teenagers are also affected. Untreated, it can lead to severe liver damage. Early screening and lifestyle changes are crucial for prevention.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/qAhPTUK
via IFTTT

Read More

Experts flag UK-India FTA over patent terms, access to drugs

Concerns are mounting in India over the UK-India Free Trade Agreement's potential impact on access to affordable medicines. Experts fear the deal may weaken compulsory licensing norms, a crucial safeguard allowing generic drug production during public health emergencies.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/p1y7eBh
via IFTTT

Read More

Over 200 cancer day care centres to be established across India: Government

The Union Health Ministry has approved the establishment of over 200 Day Care Cancer Centres (DCCCs) across India for the financial year 2025-26, including 14 in Andhra Pradesh. These centres, prioritized based on ICMR data and state proposals, will be set up in district hospitals or other government facilities.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/roF6Idu
via IFTTT

Read More

Cipla targets $1 bn US revenue in FY27

Cipla aims for $1 billion in US sales by FY27, offsetting Revlimid's patent expiry with new launches, particularly in respiratory generics like Advair and Symbicort. The company also plans to launch peptide assets and its first biosimilar in the US by Q2 FY26.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/BQEjwDN
via IFTTT

Read More

ICMR study found Covid vaccination didn't raise risk of unexplained sudden deaths among young adults: J P Nadda

An ICMR study found no link between COVID-19 vaccination and unexplained sudden deaths among young Indian adults. Instead, factors like past COVID hospitalization, family history, binge drinking, drug use, and intense physical activity were identified as key risks. Another AIIMS study confirmed heart attacks remain the leading cause of sudden deaths, with no post-pandemic pattern shift observed.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/6N2r4ds
via IFTTT

Read More

Delhi govt directs all pharmaceutical shops to install CCTV cameras to regulate sale of drugs without prescriptions

Delhi government mandates CCTV installation in all pharmacies by July 2025. This aims to stop the sale of low-quality and dual-use medicines without prescriptions. The focus is on high-risk drugs often misused by minors. Regular inspections and special drives will continue. Recent checks on anti-cancer drugs showed compliance with quality standards. These measures promote accountability and ensure drug safety.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/QZYoDGL
via IFTTT

Read More

Duty relief to boost pharma companies' access to UK drug stores

The India-UK Free Trade Agreement is set to significantly benefit India's pharma and medical device industries. Tariff reductions and streamlined regulations will drive growth. Indian companies will gain easier access to the UK market. This will boost exports, especially for generics and biosimilars. The agreement also promotes cross-border research and development.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/tSfPBnd
via IFTTT

Read More

7,000 steps a day may be the new magic number for better health: Lancet Study

A recent study in The Lancet Public Health reveals that walking at least 7,000 steps daily significantly reduces the risk of cardiovascular disease, cancer, type-2 diabetes, dementia, depression, and falls. Even 4,000 steps show health benefits compared to minimal activity. Researchers suggest 7,000 steps is a more achievable goal than 10,000 for improved health.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/O7DsMKG
via IFTTT

Read More

Natco Pharma to buy over 35% in South Africa's Adcock Ingram

Natco Pharma, based in Hyderabad, is set to acquire a 35.75% stake in Adcock Ingram, South Africa's second-largest drugmaker, for ₹2,000 crore. This all-cash deal provides Natco Pharma with a strong entry into high-growth African markets and expands its product offerings. The acquisition, expected to finalize in four months, aligns with Natco's strategy to grow in emerging markets.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/CVoQfkZ
via IFTTT

Read More

Apollo, Siemens collaborate to advance innovation in liver healthcare

Apollo Hospitals and Siemens Healthineers are collaborating to innovate liver healthcare through research. The partnership focuses on quantitative ultrasound imaging and AI-driven solutions to improve liver disease management. Their joint effort aims to enhance early detection, risk stratification, and monitoring of treatment response, ultimately improving patient outcomes and quality of life.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Q9NfDA7
via IFTTT

Read More

Natco Pharma offers to acquire nearly 36% stake in Adcock Ingram in Rs 2,100-cr deal

Natco Pharma has made a firm offer to acquire nearly 36% stake in South African drug firm Adcock Ingram Holdings for up to Rs 2,100 crore. This acquisition will provide Natco Pharma with a strong entry into the Southern African market and expand its footprint in a growing emerging market.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/IHrlhRp
via IFTTT

Read More

Biocon Biologics launches product for autoimmune diseases in Australia

Biocon's subsidiary, Biocon Biologics, has introduced Nepexto, a biosimilar to Enbrel (Etanercept), in Australia for treating autoimmune diseases like rheumatoid arthritis. Marketed through Generic Health, Nepexto aims to broaden patient access in the country.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ZeVsntL
via IFTTT

Read More

Civil society organisations urge govt to scrap animal testing in biosimilar development

Civil society organizations are urging the health ministry to eliminate animal studies in biosimilar development to lower production costs and expedite the process. They emphasize that removing these tests will enhance affordability and uphold ethical standards. The government is revising biosimilar regulations, potentially restricting animal use and prioritizing in-vitro studies, aligning with global standards to ensure safety and efficacy.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/PenTDGJ
via IFTTT

Read More

PLI scheme for bulk drugs led to import savings of Rs 1,362 cr: Govt

India's PLI scheme for bulk drugs is showing positive results. It has reduced pharma raw material imports by Rs 1,362 crore until March 2025. The scheme spurred domestic manufacturing and exports. Investment under the scheme has already surpassed initial commitments. The government has also initiated a PLI Scheme for Pharmaceuticals with a total budgetary outlay of Rs 15,000 crore.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/QJzVsyj
via IFTTT

Read More

Godavari Biorefineries secures Chinese patent for breakthrough anti-cancer molecule

Godavari Biorefineries received a patent from China for its new anti-cancer molecule. The China National Intellectual Property Administration granted the patent. Sathgen Therapeutics, Godavari's biotech division, developed the molecule. The molecule, HYDROXY-1,4-NAPHTHALENEDIONE, shows promise in fighting cancer. In vitro studies showed it inhibits cancer and cancer stem cells. It is effective against breast and prostate cancer cells.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/fey3ca6
via IFTTT

Read More

Obesity lab: India becomes ground zero for weight-loss drug race

India is emerging as a key player in the global weight management industry, driven by a rising obesity crisis and the impending patent expirations of blockbuster drugs. Pharmaceutical giants are launching innovative anti-obesity medications, while Indian companies gear up to produce affordable generic versions. Government support and incentives further position India as a major exporter of these crucial medications.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/FsK6H18
via IFTTT

Read More

ADIA signs a definitive agreement to invest $200 million in medical devices firm Meril

Abu Dhabi Investment Authority (ADIA) is set to invest $200 million for a 3% stake in medical device maker Meril, valuing the company at $6.6 billion. This investment, pending CCI approval, will support Meril's growth and research efforts.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/SehyA24
via IFTTT

Read More

Abu Dhabi Investment Authority to buy 3% stake in Micro Life Sciences for $200 mn

Abu Dhabi Investment Authority (ADIA) is set to acquire a 3% stake in the Indian medical device company, Micro Life Sciences Pvt Ltd (Meril), for USD 200 million. This investment values Meril at USD 6.6 billion, pending regulatory approval from the Competition Commission of India (CCI). Meril plans to use the funds to accelerate growth and strengthen clinical research.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/rFMbOcD
via IFTTT

Read More

Brookfield, EQT close in on Gland Pharma, but rising stock a pain

The Chinese parent has diversified investments that range from healthcare to football clubs, asset management, banks, estate, hospitality, fashion and industrials. The conglomerate has a presence across the pharma value chain from manufacturing to diagnostics and medical devices. Shanghai Fosun Pharmaceutical Co. had acquired an 86% stake in Gland Pharma in 2016 from KKR for a record deal value of $1.26 billion.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/XMPWGYU
via IFTTT

Read More

Zydus Life's plans for cancer biosimilar hit a legal hurdle

The Delhi High Court has granted an interim injunction against Zydus Lifesciences, an Ahmedabad-based drug maker, following a patent infringement case filed by Bristol Myers Squibb concerning its anticancer drug Opdyta (nivolumab).

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Q40EjHC
via IFTTT

Read More

Dr Reddy's gets seven observations from USFDA for Andhra plant

Dr Reddy's Laboratories faces scrutiny. The USFDA issued a Form 483 after inspecting their Srikakulam facility. The inspection, which occurred in July 2025, revealed seven observations. These observations relate to potential violations of the Food, Drug and Cosmetic Act. Dr Reddy's plans to address these concerns promptly. The company aims to resolve the issues within the given timeframe.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/5DHes8o
via IFTTT

Read More

Development of indigenous multi-stage Malaria vaccine 'AdFalciVax' is underway

India is developing a new malaria vaccine. The Indian Council of Medical Research is leading the effort. The vaccine is called AdFalciVax. It targets two stages of the malaria parasite. Preclinical data shows excellent efficacy. The vaccine could prevent infection and reduce transmission. ICMR plans to license the technology to manufacturers. This aims to make the vaccine widely available.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/KJ75uly
via IFTTT

Read More

Mind your posture: Doctors cite long hours in front of screen for increasing lifestyle diseases

Young professionals are increasingly facing lifestyle ailments due to prolonged sitting and screen time, leading to a 30-40% rise in muscular, spinal, eye, heart, and mental health disorders. The pressure to stay relevant in an AI-driven workplace exacerbates these issues, causing conditions like Tech Neck and Digital Fatigue Syndrome.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/NRZwo7U
via IFTTT

Read More

New dilemma looms for India’s private hospitals: More beds, but few can lie in them

India's private hospital sector faces a potential overcapacity in major cities due to significant upcoming bed additions, even as smaller towns lack sufficient beds. While demand for quality healthcare grows, driven by rising incomes and insurance coverage, analysts caution that this expansion could strain profitability.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/DpnW9w0
via IFTTT

Read More

Sprays, pills, creams...ooh, aah, ouch? India’s pain market is now a Rs 16,000 cr giant

India’s pain relief market has exploded post-pandemic, doubling to nearly ₹16,000 crore in just five years. From gels and sprays to pills like Dolo and Zerodol, pain meds are now a daily fix for everything from gym soreness to chronic stress. The shift is lifestyle-driven and increasingly normalised, but experts warn against unchecked self-medication. As the over-the-counter space booms, driven by awareness and ease of access, the line between relief and risk is getting worryingly thin.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2tuEaO7
via IFTTT

Read More

Central drugs laboratories find 55 samples to be 'not of standard quality' in June

In June 2025, central drugs laboratories discovered 55 drug samples failing quality standards, while state labs found 130 similarly substandard. The CDSCO regularly posts lists of these and spurious drugs. Additionally, one drug sample each from Bihar and Delhi, and two from Telangana, were identified as spurious, prompting investigations and regulatory action.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/vnuZJlp
via IFTTT

Read More

Kenvue ties up with API to launch India's first Cough Clinics

Kenvue, makers of Benadryl, introduces 'Cough Clinics' in partnership with the Association of Physicians of India. This initiative aims to establish ten Centers of Excellence across India. These clinics will enhance healthcare professionals' knowledge of cough evaluation. The goal is to promote science-backed approaches to treatment. The clinics will offer specialized training and tools for physicians.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/H1E9tSQ
via IFTTT

Read More

Torrent Pharma seeks CCI nod to acquire majority stake in JB Chemicals for Rs 19,500 crore

Torrent Pharmaceuticals is looking to acquire J B Chemicals and Pharmaceuticals. The deal is worth Rs 19,500 crore. The company has sought clearance from the Competition Commission of India. After the deal, Torrent will become India's second most valued pharma company. Torrent will acquire a 46.39 per cent stake from Tau Investment. It will also buy 2.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/BFv9ajx
via IFTTT

Read More